iDOVE (Q106126)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: iDOVE |
Durability of Vaccine Efficacy Against SARS-CoV-2 Infection
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | iDOVE |
Durability of Vaccine Efficacy Against SARS-CoV-2 Infection |
Statements
13 December 2023
0 references
Implements a nonparametric maximum likelihood method for assessing potentially time-varying vaccine efficacy (VE) against SARS-CoV-2 infection under staggered enrollment and time-varying community transmission, allowing crossover of placebo volunteers to the vaccine arm. Lin, D. Y., Gu, Y., Zeng, D., Janes, H. E., and Gilbert, P. B. (2021) <doi:10.1093/cid/ciab630>.
0 references
